GlobeNewswire

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
03/11/2026
Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review Vouchers (PRVs) [...]
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
03/11/2026
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approved [...]
Jushi Holdings Inc. Announces Receipt of DEA Registrations for State-Licensed Medical Cannabis Operations
03/11/2026
BOCA RATON, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) ( OTCQX: JUSH ), a vertically integrated, multi-state cannabis operator, today announced that it has [...]
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
03/11/2026
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/11/2026
SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
03/11/2026
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Elevar Therapeutics Announces Lirafugratinib (Lyrfigtu) Added to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) as Second-line Therapy for Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
03/11/2026
FORT LEE, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and [...]
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
03/11/2026
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
Crescent Biopharma Announces Grants of Inducement Awards
03/11/2026
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
03/11/2026
Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease [...]
Clinicians with Lobular Breast Cancer Launch National Effort to Raise Awareness and Advocate for Change
03/11/2026
Boston, MA, US, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Despite nearly 50,000 new U.S. diagnoses each year and incidence increasing faster than other breast cancer types, invasive lobular carcinoma (ILC) remains significantly [...]
Small business benefits made easier: Saskatchewan Blue Cross introduces Business Select®
03/11/2026
Get coverage that clicks. Business Select makes benefits simpler for small Saskatchewan businesses. SASKATOON, Saskatchewan, Nov. 03, 2026 (GLOBE NEWSWIRE) -- When you run a small business, choosing employee benefits [...]
Declaration of shares and voting rights Status as of October 31, 2026
03/11/2026
VALNEVA Declaration of shares and voting rights Status as of October 31, 2026 __________________________________________________________________________________________ Company name: VALNEVA Registered office: Îlot [...]
Déclaration d’actions et de droits de vote Statut au 31 octobre 2026
03/11/2026
VALNEVA Déclaration d’actions et de droits de vote Statut au 31 octobre 2026 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège [...]
The Menninger Clinic Reports Measurable Improvements Across Multiple Mental Health Outcomes
03/11/2026
HOUSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- The Menninger Clinic, a nationally recognized psychiatric hospital, has released its 2025 inpatient treatment outcomes data, documenting measurable improvements in mental [...]
Humanaut Health Announces Six New Locations, Expanding Its Footprint as a National Leader in Longevity and Regenerative Medicine
03/11/2026
The rollout includes a new Stem Cell Center of Excellence in Park City, with additional clinics planned in California, Texas, Kansas City and Mexico City AUSTIN, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Humanaut Health [...]
Dr. John K. Drisdale DMD, a Master of the Academy of General Dentistry, Brings Advanced Cosmetic Dentistry and Full Mouth Reconstruction to Midland, Texas
03/11/2026
Dr. John K. Drisdale, DMD, MAGD, joins fewer than 2% of general dentists in the United States and Canada who have earned Mastership in the Academy of General Dentistry. The award follows more than 1,100 hours of [...]
Ozari Health Expands Tirzepatide Compounding Pharmacy Network to Five US-Licensed 503A Pharmacies
03/11/2026
The national telehealth platform now routes compounded tirzepatide and semaglutide prescriptions to five publicly named US-licensed 503A sterile compounding pharmacies in Florida and Texas, publishes each one's location [...]
Novo Nordisk A/S - share repurchase programme
03/11/2026
Bagsværd, Denmark, 3 November 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum